Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Adeia (NASDAQ:ADEA) Stock: A High-Margin Licensing Engine Betting Big on Chips

Adeia (NASDAQ:ADEA) makes its money in an unusual way: it does not build products, it licenses the ideas behind them. The company owns a large portfolio of patents covering technologies used in media and entertainment, the systems behind digital television, streaming, program guides and …

Nitish Kishor | 21 September 2026

Baltic Dry Index Today: BDI Hits 3,370 as Capesize Rates Surge to 5,768 Points

The Baltic Dry Index is not a stock price or aCommodityquote. It is a daily freight-rate benchmark published by the Baltic Exchange in London, tracking how much it costs to charter dry bulk ships carrying raw materials such as iron ore, coal, grain, bauxite, …

Nitish Kishor | 21 September 2026

Alaunos Therapeutics (NASDAQ: TCRT) Falls 25% on $1.12 Million Offering

Alaunos Therapeutics (NASDAQ: TCRT) shares closed down 25% at $1.20 after the company announced a $1.12 million registered direct offering priced at $1.46 per share, utilizing common equity alongside pre-funded warrants to raiseCapitalintended for operational needs and general corporate uses.

Nitish Kishor | 21 September 2026

Conduit Pharmaceuticals (NASDAQ: CDT) Falls 8% Despite QIMA Skin Disease Collaboration

Conduit Pharmaceuticals Inc. (NASDAQ: CDT) shares closed down 8% at $0.17 despite the company collaborating with QIMA Life Sciences to assess tapinarof combination therapies for autoimmune skin conditions.

Nitish Kishor | 21 September 2026

Xenon Pharmaceuticals (NASDAQ: XENE) Falls 31% on Depression Program Enrollment Pause

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares closed down 31% at $39.75 after the company submitted a New Drug Application for azetukalner targeting focal onset seizures, backed by successful Phase 2b and Phase 3 trial results, while concurrently instituting a temporary enrollment pause across its …

Nitish Kishor | 21 September 2026

Xenetic Biosciences (NASDAQ: XBIO) Rises 13% on All-Stock Santersus Merger

Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares closed up 13% at $2.77 after the company entered into an all-stock acquisition agreement with Santersus AG, resulting in existing XBIO shareholders retaining roughly 15% ownership while Santersus investors secure the remaining 85% of the entity.

Nitish Kishor | 21 September 2026

Cybin (NASDAQ: CYBN) Falls 12% Despite New Barclays Overweight Rating

Cybin Inc. (NASDAQ: CYBN) shares closed down 12% at $12.37, even as the company was initiated with an Overweight rating by a Barclays analyst, who set a $35 price target on the equity.

Nitish Kishor | 21 September 2026

Telomir Pharmaceuticals (NASDAQ: TELO) Rises 10% on Preclinical AMD Data

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) shares closed up 10% at $1.23 after the company published peer-reviewed preclinical data evaluating Telomir-Zn in age-related macular degeneration, demonstrating regulated iron and copper levels, preserved retinal structure, improved visual metrics, and decreased mitochondrial oxidative stress in models.

Nitish Kishor | 21 September 2026

OS Therapies (NYSE: OSTX) Reaches European Regulatory Consensus for OST-HER2

OS Therapies Incorporated (NYSE: OSTX) reached regulatory consensus alongside European agencies regarding its adaptive Phase 3 framework evaluating OST-HER2 for resected pulmonary metastatic osteosarcoma.

Nitish Kishor | 21 September 2026

InMed Pharmaceuticals (NASDAQ: INM) Sees ADAR1 Capital Management Increase Stake

InMed Pharmaceuticals Inc. (NASDAQ: INM) saw ADAR1 Capital Management acquire roughly $117,700 in common stock through open-market transactions.

Nitish Kishor | 21 September 2026
Support

Hi! How can we help you today?

Loading…